Skip to main content
. Author manuscript; available in PMC: 2015 Jul 19.
Published in final edited form as: Leukemia. 2012 Sep 5;27(3):619–628. doi: 10.1038/leu.2012.258

Figure 1.

Figure 1

C/EBPβ expression in hematopoietic stem and progenitor cells from the bone marrow of CP-CML patients. (a) Flow cytometric analysis of lineage marker negative (Lin−) bone marrow cells from healthy donors and CP-CML patients identified CD34+ CD38− HSCs and CD34+ CD38+ myeloid progenitors (upper panels). Myeloid progenitors were further subdivided into CMPs, GMPs and MEPs based on the expression of CD45RA and CD123 (lower panels). The data shown are representative of six independent experiments. (b) Frequency of CD34+ CD38− HSCs within the Lin− fraction of bone marrow cells. Error bars indicate s.d. (healthy donors, n=6; CP-CML, n=5; *P<0.05). (c) Percentage of CMPs, GMPs and MEPs in the Lin− CD34+ CD38+ fraction. Error bars indicate s.d. (healthy donors, n=6; CP-CML, n=5; *P<0.001). (d) C/EBPβ mRNA levels in purified HSCs, CMPs, GMPs and MEPs. Results were normalized to the expression level of HSCs from healthy donors (healthy donors, n = 6; CP-CML, n = 5; *P<0.05; **P<0.01).